Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRGAP3 antisense RNA 4 (SRGAP3-AS4) is a human long non-coding RNA (lncRNA) transcribed from the antisense strand of the SRGAP3 gene[3]. Like other antisense RNAs, it likely participates in regulating gene expression, potentially through mechanisms such as transcriptional interference, chromatin remodeling, or direct RNA-RNA interaction[4]. While SRGAP3 protein is known to have brain-specific functions and roles in cytoskeletal signaling and neurodevelopment[1], there is little experimentally validated information regarding the specific roles or biological significance of SRGAP3-AS4. The broader lncRNA and antisense RNA family have been increasingly recognized for their regulatory capacity, with involvement in processes such as epigenetic silencing, X-chromosome inactivation, and possibly tumorigenesis and drug resistance, but direct functions for SRGAP3-AS4 are currently unknown[4]. Key points: - SRGAP3-AS4 is a non-protein coding, antisense long non-coding RNA. - It is transcribed opposite to the SRGAP3 gene and may have roles in modulation of gene expression. - It is not established as a receptor, enzyme, or direct therapeutic target. - There are no known drugs, biomarkers, or safety concerns specifically associated with SRGAP3-AS4. - The scientific literature provides substantially more data on antisense RNA biology generally than for this specific transcript[3][4].
Not applicable for SRGAP3-AS4. For antisense RNAs in general, mechanisms may include blocking translation, promoting degradation, or recruiting chromatin modifiers, but SRGAP3-AS4-specific mechanisms are not reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRGAP3 antisense RNA 4 (non-protein coding) (SRGAP3-AS4).